The life sciences industry continues to navigate significant legal and business developments across intellectual property, regulatory compliance, commercialization, and emerging technologies. Companies face increasing pressure to protect innovation while adapting to a rapidly evolving legal landscape.
Neal Gerber Eisenberg’s Life Sciences team advises pharmaceutical, biotechnology, medical device, and healthcare companies on the legal issues that shape their businesses and growth strategies.
Featured Conference Session
Hikma v. Amarin: Skinny Labeling is Now the Law of the Land
NGE Intellectual Property Partner Emer Simic joins industry and in-house leaders to examine one of the most significant pharmaceutical patent decisions in recent years.
In a unanimous decision, the U.S. Supreme Court reaffirmed the viability of the Section viii “skinny label” pathway and clarified the standard for induced patent infringement claims. The ruling is expected to have lasting implications for branded and generic pharmaceutical manufacturers, patent litigation strategy, and product labeling decisions.
Session topics include:
- Key takeaways from Hikma v. Amarin
- The future of skinny labeling
- Active inducement of infringement following the decision
- Implications for branded and generic drug manufacturers
- Potential impact on future pharmaceutical patent disputes
Supporting the Life Sciences Industry
NGE advises life sciences companies on a wide range of business and legal matters, including:
- Intellectual property strategy and litigation
- Hatch-Waxman and biosimilar disputes
- Licensing and commercial agreements
- Regulatory and compliance issues
- Data privacy and cybersecurity
- Emerging technology and AI-related risks
Connect With Our Team
Attending the conference? We welcome the opportunity to discuss developments affecting the life sciences industry and the issues most important to your organization.
